The company touted the planned site as being a state-of-the-art facility that will integrate laboratory and office space to strengthen development capabilities. The aim is to reinforce I-Mab's ability to conduct global clinical studies across China and the U.S. The company did not indicate when the site would be operational.

The San Diego site will serve as one of the company's strategic sites for global drug development efforts. In addition, it will include a biomarker platform that will support current and future clinical trials. I-Mab said the new facility will be part of the company's U.S. R&D center together with its global clinical development site that was established in 2018 in Gaithersburg, MD.

The new site will serve as a specialized research site for worldwide development efforts in addition to hiring talent in immuno-oncology, translational medicine, chemistry, manufacturing, and controls.